Search
Maryland Paid Clinical Trials
A listing of 2676 clinical trials in Maryland actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1261 - 1272 of 2676
Maryland is currently home to 2676 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Study Evaluating APG777 in Atopic Dermatitis
Recruiting
This is a two-part study that will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD). Part A (Proof-of-concept) and Part B (Dose-regimen Finding) will evaluate the safety and efficacy of various induction and maintenance dose regimens of APG777 compared to placebo. The study duration for any individual participant will be up to 106 weeks which includes: screening, induction, maintenance, and post-treatment follow-up periods. Participants ra... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Investigational Site # 2, Rockville, Maryland
Conditions: Atopic Dermatitis
Tocilizumab in Lung Transplantation
Recruiting
This is a trial in which 350 primary lung transplant recipients will be randomized (1:1) to receive either Tocilizumab (six doses over 20 weeks) plus standard triple maintenance immunosuppression or placebo (sterile normal saline) plus standard triple maintenance immunosuppression (Tacrolimus, Mycophenolate Mofetil, corticosteroids).
The primary objective is to test the hypothesis that treatment with triple maintenance immunosuppression plus Tocilizumab (TCZ) is superior to triple maintenance i... Read More
Gender:
ALL
Ages:
Between 12 years and 75 years
Trial Updated:
03/20/2025
Locations: University of Maryland Medical Center (Site #: 71138), Baltimore, Maryland
Conditions: Lung Transplant
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
Recruiting
The primary objective of the study is to determine the effect of seralutinib on improving exercise capacity in subjects with WHO Group 1 PAH who are FC II or III. The secondary objective for this trial is to determine time to clinical worsening.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/20/2025
Locations: University of Maryland Medical Center, Baltimore, Maryland
Conditions: Pulmonary Arterial Hypertension
A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
Recruiting
This is a Phase 3, 2-arm, randomized, open-label, global, multicenter study comparing the efficacy of ripretinib to sunitinib in participants with GIST who progressed on first-line treatment with imatinib, harbor co-occurring KIT exons 11+17/18 mutations, and are without KIT exon 9, 13, or 14 mutations. Upon disease progression as determined by an independent radiologic review, participants randomized to sunitinib will be given the option to either crossover to receive ripretinib 150 mg QD or di... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: GIST
Establishment of Genomic and Phenotypic Database for Niemann-Pick Disease, Type C
Recruiting
Background:
Niemann-Pick type C (NPC) disease is a rare, progressive neurodegenerative disease that affects mainly the brain, liver, and spleen but also other parts of the body. There is no cure for NPC, and symptoms only get worse over time. Symptoms can include seizures, difficulty moving or talking, or dementia. But symptoms can vary among different people with the disease. Some may have seizures, while others do not, for example. Some people begin showing symptoms in childhood; in others, s... Read More
Gender:
ALL
Ages:
3 months and above
Trial Updated:
03/20/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Niemann-Pick Disease, Type C
Investigate Efficacy and Safety of Carisbamate As Adjunctive Treatment for Seizures Associated with LGS in Children and Adults
Recruiting
The primary objective is to evaluate the efficacy of carisbamate (YKP509) as adjunctive treatment in reducing the number of drop seizures (tonic, atonic, and tonic-clonic) compared with placebo in pediatric and adult subjects (age 4-55 years) diagnosed with Lennox Gastaut Syndrome (LGS).
Gender:
ALL
Ages:
Between 4 years and 55 years
Trial Updated:
03/20/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Seizures, Lennox Gastaut Syndrome
Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
Recruiting
Primary objective: To evaluate the safety and tolerability of cenobamate in pediatric subjects 2-17 years of age with partial-onset (focal) seizures
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
03/20/2025
Locations: Mid-Atlantic Epilepsy and Sleep Center, Bethesda, Maryland
Conditions: Partial Epilepsy
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
Recruiting
This study will compare the safety and effects of HAI floxuridine and dexamethasone combined with the standard chemotherapy drugs gemcitabine and oxaliplatin (GemOx) with those of GemOx alone in people with untreated cholangiocarcinoma that cannot be removed with surgery. The researchers want to find out whether the study treatment works better than the standard chemotherapy to delay progression of disease. For the study treatment to be considered better than the standard treatment, the study tr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: National Heart, Lung, and Blood Institute (NIH) (Data Collection Only), Bethesda, Maryland
Conditions: Intrahepatic Cholangiocarcinoma
Study to Evaluate Efficacy, Safety and Tolerability of HM15211(efocipegtrutide) in Subjects
Recruiting
This study is a phase 2 study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/20/2025
Locations: University of Maryland Medical Center, Baltimore, Maryland
Conditions: NASH - Nonalcoholic Steatohepatitis
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
Recruiting
This is a phase II trial of durvalumab and tremelimumab in combination of platinum-based chemotherapy. Patients with stage IV Non-Small-Cell-Lung Cancer (NSCLC) with human immunodeficiency virus (HIV) infection will be eligible. Patients will receive standard platinum-based chemotherapy plus durvalumab for 4 cycles (every 3 weeks), followed by durvalumab (with or without pemetrexed for non-squamous NSCLC) maintenance therapy. It is hypothesized that Durvalumab and tremelimumab in combination wit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland
Conditions: Carcinoma, Non-Small Cell Lung
An International, Multicenter, Prospective Registry on Post-traumatic Long Bones Defects
Recruiting
Long bone defect (LBD) is defined as a focalized loss of bone tissue in any long bone of the upper or lower extremity. Long bone defects are a complex problem, that may arise as a complication of many different pathologies, such as trauma, tumors or infection. Whereas post-traumatic defects are the largest group.
Reports estimate that there are almost 4 million bone grafting procedures worldwide per year. However, limb reconstruction in the context of a bony defect is challenging and up to date... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Sinai Hospital of Baltimore, Baltimore, Maryland
Conditions: Limb Fracture, Bone Loss
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
Recruiting
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Luminis Health Research Institute, Annapolis, Maryland
Conditions: Non-Small Cell Lung Cancer